EGFR and non-small cell lung carcinoma: In NSCLC patients, palmitoylation of EGFR oncoprotein at Cys797 site by ZDHHC1, ZDHHC2, and/or ZDHHC21 enzymes (Zinc finger DHHC-type containing enzymes) leads to receptor dimerization, stability, and its subsequent activation (3).When EGFR palmitoylation is inhibited using broad spectrum protein palmitoylation inhibitors such as 2-bromopalmitate (2-BP), the lethal efficacy of its targeted inhibitor, Gefitinib increases (3).